IPOL market forecast points to travel, births and immunization programs as growth drivers

The Business Research Company says the global IPOL market is expanding on the back of polio eradication efforts, rising travel and migration, higher birth rates and government vaccination programs. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - The IPOL market tracks demand for an inactivated poliovirus vaccine that remains important for routine childhood immunization, travel medicine and polio eradication efforts. - The market outlook matters for governments, health systems and vaccine suppliers as they balance outbreak prevention, booster coverage and cold-chain capacity.

What happened: - The Business Research Company published its Global Market Report 2026 for the IPOL market, covering market size, trends and forecasts for 2026-2035. - The report says the IPOL market expanded during the historical period and is expected to keep growing through the forecast period. - The report identifies North America as the largest regional market in 2025. - The report projects Asia-Pacific as the fastest-growing region over the forecast period. - Download a free sample of the IPOL market report - View the full IPOL market report

The details: - IPOL is an injectable vaccine containing inactivated strains of poliovirus types 1, 2 and 3. - The vaccine works by prompting the immune system to produce antibodies that neutralize poliovirus if exposure occurs. - The report cites international polio eradication campaigns, replacement of live vaccines over safety concerns, government immunization drives and support from global health organizations as major historical growth drivers. - The report points to ongoing surveillance for polio eradication, broader adult booster vaccination programs, travel-related vaccination demand, stable public health funding and cold-chain improvements as future growth drivers. - The report flags persistent reliance on inactivated polio vaccines, a shift away from oral polio vaccines, expanded routine immunization coverage and stronger travel and adult immunization strategies as key trends. - The report says rising global travel and migration are boosting demand because many countries require proof of polio vaccination for entry. - UN Tourism data released in May 2024 showed 285 million tourists traveled internationally in the first quarter of 2024, up 20% from the same period in 2023. - Rising birth rates are also supporting demand because more infants and young children increase the need for routine vaccination. - The US Centers for Disease Control and Prevention reported a 1% increase in US births from 2023 to 2024, to 3,628,934 newborns. - Government-led vaccination initiatives remain a major demand driver because they expand access, reduce transmission and strengthen routine immunization schedules. - The CDC said global immunization coverage remained stable in 2022-2023, with 89% coverage for the first dose of diphtheria-tetanus-pertussis vaccine, 84% for the third dose and 83% for the first dose of measles-containing vaccine. - The report says its 2026 market reports now include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The market’s growth story is less about a single new technology than about sustained public-health policy, travel patterns and demographic change. - The report’s focus on travel and adult boosters suggests demand is broadening beyond infant immunization, which could support steadier vaccine use even as eradication efforts progress. - The regional split implies mature demand in North America and faster expansion opportunities in Asia-Pacific, where population growth and immunization programs can lift volume.

What’s next: - The report expects continued demand from eradication surveillance, routine vaccination programs and travel immunization requirements. - The next phase of market growth will likely depend on how effectively governments maintain immunization coverage and cold-chain logistics while polio eradication efforts continue.

The bottom line: - IPOL demand is being pulled by public health campaigns, cross-border travel and newborn vaccination needs, with Asia-Pacific positioned as the next major growth engine.